Switzerland secures three million doses of Pfizer/BioNTech vaccine
The Pfizer/BioNTech employs the novel mRNA technology.
Keystone / Biontech Se / Handout
Switzerland has signed an agreement with a third manufacturer of Covid-19 vaccines for three million doses. A contract has been signed with Pfizer and BioNTech, the co-producers of the mRNA vaccine, pending safety approval from the health regulator Swissmedic.
This content was published on
2 minutes
swissinfo.ch/mga
Português
pt
Suíça obtém três milhões de doses da vacina Pfizer/BioNTech
Some 4.5 million doses of another vaccine have already been agreed with United States pharma company Moderna and another 5.3 million doses from the British-Swedish firm AstraZeneca. The government said on MondayExternal link that membership of the World Health Organization COVAXExternal link initiative grants vaccine coverage to 20% of the Swiss population.
The Pfizer/BioNTech vaccine would require two doses per person, meaning the initial supply would cover 1.5 million people.
In a press release the government said “the quality, safety and efficacy of Covid-19 vaccines are crucial. They must be approved by Swissmedic and recommended by the Federal Office of Public Health before being used”.
Earlier this month Swissmedic said it was still waiting for important data on safety, efficacy and quality from all three manufacturers.
Free of charge
Switzerland has set aside CHF400 million ($448 million) to secure supplies of vaccines. Vaccines will be offered free of charge with priority given to the most vulnerable groups and health workers. The army will be deployed to ensure stockage and distribution and to set up vaccination centres.
The government said on Monday that it was still in discussions with various other vaccine manufacturers.
“Since it is not yet clear which vaccines will prevail, it is targeting a number of SARS-CoV-2 vaccines based on different technologies (mRNA, protein-based and vector-based),” it said.
Also on Friday, Swissmedic said it had received an application from a vaccine developed by Janssen Pharmaceutical, a division of US firm Johnson & Johnson. The vaccine candidate Ad26.COV2.Sis a recombinant viral-vector vaccine based on a human adenovirus.
Swissmedic said this is the fourth vaccine it is reviewing under its “rolling procedure” that allows manufacturers to submit the results of test studies in stages.
More
More
Swiss Politics
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
Swiss president unveils new theme park dedicated to Saint Bernards
This content was published on
The new Barryland theme park in Martigny, south-western Switzerland, was officially opened on Thursday in the presence of Swiss President Karin Keller-Sutter.
Swiss court rejects diplomats’ daughter’s request for permanent residence
This content was published on
The 17-year-old daughter of a diplomatic couple working in Switzerland is not entitled to a residence permit, the Federal Administrative Court has ruled.
Swiss hospitals urge faster recognition of foreign medical qualifications
This content was published on
Foreign doctors wishing to work in a Swiss hospital have to wait several months for their diplomas to be recognised, a situation the hospital association H+ calls 'untenable'.
Switzerland to introduce code of conduct for collecting referendum signatures
This content was published on
Commercial collectors of signatures for initiatives and referendums could be given a legally non-binding code of conduct. This proposal comes from the Federal Chancellery following the discovery of thousands of falsified signatures.
Priest in Switzerland accused of sexually assaulting minors
This content was published on
The trial of a priest accused of sexually abusing nine people opened on Thursday in the Ticino cantonal criminal court in Lugano, southern Switzerland.
Two out of three people in Switzerland use more than one language daily
This content was published on
Two out of three people in Switzerland regularly use several languages in their everyday lives, most often the country's national languages.
Destroyed Swiss village of Blatten to be rebuilt within four years
This content was published on
After the devastating landslide, Blatten in Valais should be standing again by 2029. Municipal president Matthias Bellwald confirmed the corresponding plans to the Keystone-SDA news agency on Wednesday, which he had presented at a municipal meeting the previous evening.
Lufthansa mulls importing its future Boeing aircraft via Switzerland
This content was published on
Buying new Boeing aircraft from the United States via Switzerland could reduce the US trade deficit with Switzerland and avoid punitive customs duties, says a newspaper report.
Swiss environment minister ‘hopeful’ plastic pollution treaty within reach
This content was published on
Swiss Environment Minister Albert Rösti said he's "hopeful until the end" that an ambitious agreement against plastic pollution can be negotiated by the end of the year.
Switzerland must pay more than originally planned for US F-35 fighter jets
This content was published on
Switzerland has been unable to push through a fixed-price deal (CHF6 billion) with the United States for 36 new F-35 fighter jets.
Incomplete data stalls Swiss authorisation of Covid-19 vaccines
This content was published on
Switzerland’s medical regulator says it lacks the necessary information to sign off on three different vaccines ordered by the government.
This content was published on
With a death toll of over 5,000, Switzerland (population 8.5 million) expects to launch its coronavirus vaccination campaign in early January.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.